530 related articles for article (PubMed ID: 25940718)
21. Update on Hereditary Colorectal Cancer: Improving the Clinical Utility of Multigene Panel Testing.
Lorans M; Dow E; Macrae FA; Winship IM; Buchanan DD
Clin Colorectal Cancer; 2018 Jun; 17(2):e293-e305. PubMed ID: 29454559
[TBL] [Abstract][Full Text] [Related]
22. Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations.
Nielsen M; Hes FJ; Vasen HF; van den Hout WB
BMC Med Genet; 2007 Jul; 8():42. PubMed ID: 17605803
[TBL] [Abstract][Full Text] [Related]
23. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
[TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness of screening strategies for Lynch syndrome.
Barzi A; Sadeghi S; Kattan MW; Meropol NJ
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25794514
[TBL] [Abstract][Full Text] [Related]
25. Introduction to molecular and clinical genetics of colorectal cancer syndromes.
Tops CM; Wijnen JT; Hes FJ
Best Pract Res Clin Gastroenterol; 2009; 23(2):127-46. PubMed ID: 19414141
[TBL] [Abstract][Full Text] [Related]
26. Next-Generation Sequencing vs Culture-Based Methods for Diagnosing Periprosthetic Joint Infection After Total Knee Arthroplasty: A Cost-Effectiveness Analysis.
Torchia MT; Austin DC; Kunkel ST; Dwyer KW; Moschetti WE
J Arthroplasty; 2019 Jul; 34(7):1333-1341. PubMed ID: 31005439
[TBL] [Abstract][Full Text] [Related]
27. Genetic testing in hereditary colorectal cancer: indications and procedures.
Terdiman JP; Conrad PG; Sleisenger MH
Am J Gastroenterol; 1999 Sep; 94(9):2344-56. PubMed ID: 10483990
[TBL] [Abstract][Full Text] [Related]
28. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer.
Mvundura M; Grosse SD; Hampel H; Palomaki GE
Genet Med; 2010 Feb; 12(2):93-104. PubMed ID: 20084010
[TBL] [Abstract][Full Text] [Related]
29. Caring for patients at risk for hereditary colorectal cancer.
Greco K
Oncology (Williston Park); 2007 Feb; 21(2 Suppl Nurse Ed):29-38; discussion 39. PubMed ID: 17476735
[TBL] [Abstract][Full Text] [Related]
30. Clinical exome sequencing vs. usual care for hereditary colorectal cancer diagnosis: A pilot comparative effectiveness study.
Niu X; Amendola LM; Hart R; Bennette CS; Heagerty P; Horike-Pyne M; Trinidad SB; Rosenthal EA; Comstock B; Nefcy C; Hisama FM; Bennett RL; Grady WM; Gallego CJ; Tarczy-Hornoch P; Fullerton SM; Burke W; Regier DA; Dorschner MO; Shirts BH; Robertson PD; Nickerson DA; Patrick DL; Jarvik GP; Veenstra DL
Contemp Clin Trials; 2019 Sep; 84():105820. PubMed ID: 31400517
[TBL] [Abstract][Full Text] [Related]
31. Establishing a clinical and molecular diagnosis for hereditary colorectal cancer syndromes: Present tense, future perfect?
Jansen M; Menko FH; Brosens LA; Giardiello FM; Offerhaus GJ
Gastrointest Endosc; 2014 Dec; 80(6):1145-55. PubMed ID: 25434663
[No Abstract] [Full Text] [Related]
32. [Genetic aspects of colorectal cancer].
Abramowicz M
Rev Med Brux; 2001 Sep; 22(4):A199-202. PubMed ID: 11680173
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness and budget impact analysis of a population-based screening program for colorectal cancer.
Pil L; Fobelets M; Putman K; Trybou J; Annemans L
Eur J Intern Med; 2016 Jul; 32():72-8. PubMed ID: 27157827
[TBL] [Abstract][Full Text] [Related]
34. Use of multigene-panel identifies pathogenic variants in several CRC-predisposing genes in patients previously tested for Lynch Syndrome.
Hansen MF; Johansen J; Sylvander AE; Bjørnevoll I; Talseth-Palmer BA; Lavik LAS; Xavier A; Engebretsen LF; Scott RJ; Drabløs F; Sjursen W
Clin Genet; 2017 Oct; 92(4):405-414. PubMed ID: 28195393
[TBL] [Abstract][Full Text] [Related]
35. Clinical implications of our advancing knowledge of colorectal cancer genetics: inherited syndromes, prognosis, prevention, screening and therapeutics.
Gryfe R
Surg Clin North Am; 2006 Aug; 86(4):787-817. PubMed ID: 16905411
[TBL] [Abstract][Full Text] [Related]
36. Hereditary colorectal cancer.
Lynch HT; de la Chapelle A
N Engl J Med; 2003 Mar; 348(10):919-32. PubMed ID: 12621137
[No Abstract] [Full Text] [Related]
37. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
J Clin Oncol; 2015 Apr; 33(10):1112-8. PubMed ID: 25691669
[TBL] [Abstract][Full Text] [Related]
38. Economic evaluation of the familial cancer programme in Western Australia: predictive genetic testing for familial adenomatous polyposis and hereditary non-polyposis colorectal carcinoma.
Breheny N; Geelhoed E; Goldblatt J; Ee H; O'Leary P
Community Genet; 2006; 9(2):98-106. PubMed ID: 16612060
[TBL] [Abstract][Full Text] [Related]
39. Role of surgery in familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer (Lynch syndrome).
Smith KD; Rodriguez-Bigas MA
Surg Oncol Clin N Am; 2009 Oct; 18(4):705-15. PubMed ID: 19793576
[TBL] [Abstract][Full Text] [Related]
40. [Hereditary colorectal carcinoma: predictive diagnosis and genetic counseling].
Mangold E; Friedl W; Propping P
Praxis (Bern 1994); 2001 Mar; 90(12):490-6. PubMed ID: 11324308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
